| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 02/15/2005 | US6855689 Anticancer agents |
| 02/15/2005 | US6855532 Gene therapy; drug screening |
| 02/15/2005 | US6855528 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 02/15/2005 | US6855512 Phenylacetic or heteroarylacetic acid derivatives; retinoid like activity |
| 02/15/2005 | US6855510 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 02/15/2005 | US6855350 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 02/15/2005 | CA2156821C Lidocaine aerosol anaesthetic |
| 02/15/2005 | CA2123232C Pharmaceutical compositions containing ebastin or analogs thereof |
| 02/10/2005 | WO2005012543A2 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation |
| 02/10/2005 | WO2005012352A1 SOLUBLE HUMAN INTERLEUKIN 18 RECEPTOR-α, METHOD OF ASSAYING THE SAME, ASSAY KIT AND MEDICINAL COMPOSITION |
| 02/10/2005 | WO2005012269A1 Novel azole compound |
| 02/10/2005 | WO2005012268A1 Sulfonamide derivative having isoxazole ring |
| 02/10/2005 | WO2005012251A1 Therapeutic agent for chronic obstructive pulmonary disease and method of treatment for chronic obstructive pulmonary disease with the same |
| 02/10/2005 | WO2005012248A1 Benzylamine derivative |
| 02/10/2005 | WO2005011674A1 Preventive and/or therapeutic agents for bronchial asthma |
| 02/10/2005 | WO2005011659A1 Use of n-alkanols as activators of the cftr channel |
| 02/10/2005 | WO2004110415A3 Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
| 02/10/2005 | WO2002064626A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 02/10/2005 | US20050033055 Edg receptor agonists |
| 02/10/2005 | US20050032874 Indole derivatives |
| 02/10/2005 | US20050032858 Novel heterocyclic compound and anti-inflamatory agent |
| 02/10/2005 | US20050032851 E. g.,N-[[4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide; side effect reduction; non-steroidal antiinflammatory agents; antiarthritic agents; analgesics; antipyretics; acylation of the corresponding sulfoamide by an anhydride a solvent and base |
| 02/10/2005 | US20050032825 rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis |
| 02/10/2005 | US20050032820 Novel spiro compounds |
| 02/10/2005 | US20050032815 Preventing dermatitis in a human by administering a composition consisting of therapeutically effective amounts of optically pure (-) cetirizine or salt thereof, and a leukotriene inhibitor or salt thereof; synergistic mixture; also useful as asthma treatment |
| 02/10/2005 | US20050032792 Peptidyl spiroheterocyclic, amidino and guanidino compounds; reversible inhibitors of the cysteine protease cathepsin S, K, F, L and B; useful in the treatment of autoimmune and other related diseases |
| 02/10/2005 | US20050032779 enzyme inhibitors such as 2-[4-(4-Dimethylaminophenyl)piperazin-1-yl]4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one, used for treating or preventing disorders in which poly/ADP-ribose/ polymerase is involved |
| 02/10/2005 | US20050032775 Aztreonam L-lysine and methods for the preparation thereof |
| 02/10/2005 | US20050032772 Compounds useful as reversible inhibitors of cysteine proteases |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032724 Multidrug Resistance Protein 1 (MRP1); mutagenesis |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032686 administering to a manimal a therapeutically effective amount of ES-62 ( a glycoprotein) to treat an inflammatory disease: arthritis and chronic obstructive pulmonary disease |
| 02/10/2005 | US20050032684 Use of a peptide which activates guanylate-cyclase c for the treatment of respiratory airway problems via the airways, medicament, inhaltion devices and method of diagnosis |
| 02/10/2005 | US20050032214 Cell-specific expression/replication vector |
| 02/10/2005 | US20050032161 Novel xanthine phosphoribosyl transferase |
| 02/10/2005 | US20050032036 Using drug resistant bacterial strains as tools for identifying bactericidal phage; preventing staphylococcus infection |
| 02/10/2005 | US20050031674 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 02/10/2005 | US20050031646 Immunogens; polysaccharide conjugate antigens derived from pathogenic bacterium conjugated to protein D from Haemophilus influenzae |
| 02/10/2005 | US20050031609 Compositions for use in treating ige-associated disorders |
| 02/10/2005 | US20050029705 Extrusion die |
| 02/10/2005 | DE10332712A1 Verwendung von c9,t11-Isomeren der konjugierten Linolsäure Use of c9, t11 isomer of conjugated linoleic acid |
| 02/10/2005 | CA2534460A1 Benzylamine derivative |
| 02/10/2005 | CA2534354A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | CA2534074A1 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | CA2533600A1 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation |
| 02/09/2005 | EP1505150A1 Novel proteins and dnas thereof |
| 02/09/2005 | EP1505068A1 PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
| 02/09/2005 | EP1505067A1 4,4-disubstituted piperidine derivatives having ccr3 antagonism |
| 02/09/2005 | EP1505061A1 Compound exhibiting pgd 2 receptor antagonism |
| 02/09/2005 | EP1504764A1 Treatment of liver fibrosis with antagonists of alpha V beta 6 integrin |
| 02/09/2005 | EP1504756A1 Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504027A2 Adipocyte complement related protein zacrp8 |
| 02/09/2005 | EP1504008A1 7-aminoimidazotriazones |
| 02/09/2005 | EP1504006A1 5-ethyl-imidazo[5,1-f][1,2,4]triazin-4(3h)-ones as phosphodiesterase inhibitors |
| 02/09/2005 | EP1503996A1 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| 02/09/2005 | EP1503992A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors |
| 02/09/2005 | EP1503801A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/09/2005 | EP1503794A1 Methods of treatement using ctla-4 antibodies |
| 02/09/2005 | EP1503791A2 Methods of therapy for inducing tolerance |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503766A2 Compositions and methods for treating emphysema |
| 02/09/2005 | EP1503754A1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| 02/09/2005 | EP1503739A1 Sustained release of guaifenesin combination drugs |
| 02/09/2005 | EP1503730A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
| 02/09/2005 | EP1436252A4 Hydroxyfattysulfonic acid analogs |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1385854B1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP1140939B1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods |
| 02/09/2005 | EP1079813B1 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 02/09/2005 | EP1071417B1 Use of cannabidiol as anti-inflammatory agent |
| 02/09/2005 | EP0700438B1 Opioid receptors: compositions and methods |
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578779A Small organic molecule regulators of cell proliferation |
| 02/09/2005 | CN1578776A Heterocyclic retinoid compounds |
| 02/09/2005 | CN1578768A Anthranilic acid amides and pharmaceutical use thereof |
| 02/09/2005 | CN1578767A Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2005 | CN1578672A Rsv基因表达疫苗 Rsv gene expression vaccine |
| 02/09/2005 | CN1578670A Use of lactalapoprotein in prevention and treatment of microbial or virus infection |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578661A Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 02/09/2005 | CN1188416C Oxathiepino [6,5-b]dihydropyridines,and related compositions and preparation methods |
| 02/09/2005 | CN1188415C Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5)for treatment of sexual dysfunction |
| 02/09/2005 | CN1188412C Process for preparing crystalline form 1 of cabergoline |
| 02/09/2005 | CN1188410C Nonsteroid IL-5 inhibitor, its preparation method and medical composition containing the same inhibitor |
| 02/09/2005 | CN1188388C Aminobenzophenones as inhibitors of interleukin and TNF |
| 02/09/2005 | CN1188164C Compositions and method for regulating phagocytosis and ICAM-1 expression |
| 02/09/2005 | CN1188163C Medicine for curing cough due to exopathy for children and preparation method thereof |
| 02/09/2005 | CN1188162C Method for preparing Gongjinle medicinal liquor for treating tracheitis |
| 02/09/2005 | CN1188129C Pectoral |
| 02/09/2005 | CN1188111C Dry powder compositions having improved dispersivity |
| 02/08/2005 | US6852889 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/08/2005 | US6852740 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 02/08/2005 | US6852734 Indole wherein A is an oxygen atom or a nitrogen atom which nitrogen atom is optionally substituted with an alkyl group, and (i) R1 and R2 each stand for a hydrogen atom or an alkyl group, independently, or (ii) R1 and R2 as taken together form |
| 02/08/2005 | US6852729 Macrolides |
| 02/08/2005 | US6852728 Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them |